DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Colorectal Cancer (CRC) Cetuximab Elderly Frail

Information source: European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Colorectal Cancer Metastatic

Intervention: Cetuximab (Drug); 5-fluorouracil (Drug); leucovorin (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: European Organisation for Research and Treatment of Cancer - EORTC

Official(s) and/or principal investigator(s):
Marc Peeters, MD, PhD, Study Chair, Affiliation: UNIVERSITAIR ZIEKENHUIS ANTWERPEN, Edegem, Belgium
Ulrich Wedding, MD, Study Chair, Affiliation: UNIVERSITAETSKLINIKUM JENA, Jena, Germany

Summary

OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC) prolongs Progression Free Survival, compared with 5-fluorouracil alone.

Clinical Details

Official title: Treatment of Patients With KRAS Wild Type Advanced Colorectal Cancer (CRC) With 5-Fluorouracil (5-FU) or 5- FU Plus an Epidermal Growth Factor Receptor (EGFR) Inhibitor (Cetuximab) Based on a Comprehensive Geriatric Assessment (CGA).

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Progression free survival

Secondary outcome:

Overall Survival

Response Rate

Change in Instrumental Activities of Daily Living (IADL) score

Change in G8 geriatric assessment screening tool

Change in social situation

Score of Quality of Life (EORTC-QLQ C30 and QLQ-ELD14)

Occurrence of adverse events

Health Economy assessments

Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by G8 instrument

Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by Instrumental Activities of Daily Life (IADL) questionnaire

Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire

Detailed description: The primary efficacy analyses will be performed on the Intention-to-treat population. The safety analyses will be performed on the Safety population.

- Median PFS and OS in each treatment arm with its 95% CI, estimated by the Kaplan-Meier

technique

- Response rates by treatment arm with their exact 95% CI

- IADL sum score, G8 sum score and social situation by treatment arm at baseline and at

each timepoint of assessment

- QoL scores from the EORTC QLQ-C30 and QLQ-ELD14 modules by treatment arm at baseline

and at each timepoint of assessment

- Safety data by treatment arm in the Safety population. Worst toxicity grade over all

cycles according to the CTCAE criteria version 4. 0 by treatment arm.

- Pharmaco-economics evaluation

Summary of proposed Phase II trial characteristics: 1. Total number of randomized patients: 150. 2. Total number of events at phase II analysis for primary endpoint: 110. 3. Total number of patients screened over the phase II: 250. 4. Total number of patients treated with cetuximab for the Phase II study: 75. 5. Maximum study duration: 19 months. In the present study, HRQoL is an important secondary endpoint. The objective of the HRQoL data collection in this Phase II trial is to assess the impact of the addition of cetuximab on patients' HRQoL during treatment. The hypothesis is that there will be no difference in patients' HRQoL between both treatment arms during treatment. The HRQoL domains (from the EORTC QLQ-C30 module) which are expected to be affected by treatment (to the same extent in both arms) are Global health status, Fatigue, Pain and Stool habits.

Eligibility

Minimum age: 70 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Pathologically confirmed metastatic colorectal cancer

- Measurable disease according to RECIST V1. 1

- Histological local review and analysis of KRAS

- Age ≥ 80 or ≥ 70 in combination with functional restrictions defined as limitation in

at least 2 of 8 IADL

- WHO performance status 0, 1 or 2

- Adequate bone marrow reserves, hepatic function & renal function

- Normal 12 lead ECG without clinically significant abnormalities

- Written informed consent before randomization according to ICH/EU GCP, and local,

national and international regulations Exclusion Criteria:

- Prior systemic chemotherapy for metastatic disease

- Previous exposure to EGFR or VEGF/VEGFR targeted therapy

- Patients may have received chemotherapy in the adjuvant or neoadjuvant setting (CRC).

The treatment-free interval should be 6 months or more from the end of (neo-)adjuvant therapy

- Previous radiotherapy, either in the adjuvant setting or for the treatment of bone

metastases, is allowed provided that the measurable lesions are outside the radiation fields

- Persistence of clinically relevant treatment-related toxicities from previous

chemotherapy and/or radiotherapy (adjuvant or neo-adjuvant setting)

- Treatment with other investigational drugs or treatment in another clinical trial

within the past four weeks before start of treatment or concomitantly with this trial

- Known alcohol or drug abuse

- Clinically significant cardiovascular disease

- Evidence of uncontrolled medical comorbidities despite adequate treatment

- Patients who have suffered a cerebrovascular accident or transient ischemic attack

within the past 12 months

- History, within the past 5 years, of malignancies other than CRC

- Psychological, familial, sociological, or geographical condition potentially

hampering compliance with the study protocol and followup schedule

Locations and Contacts

ZNA Middelheim, Antwerpen, Belgium

Cliniques Universitaires Saint-Luc, Brussels, Belgium

Hopital Universitaire Brugmann, Brussels, Belgium

Universitair Ziekenhuis Antwerpen, Edegem, Belgium

Universitair Ziekenhuis Gent, Gent, Belgium

Hopital De Jolimont, Haine St Paul, Belgium

C.H.U. Sart-Tilman, Liege, Belgium

AZ Damiaan, Oostende, Belgium

AZ Turnhout - Campus Sint Elisabeth, Turnhout, Belgium

Centre Hospitalier Peltzer-La Tourelle, Verviers, Belgium

Bank Of Cyprus Oncology Centre, Nicosia, Cyprus

Seconda Universita Degli Studi Di Napoli, Napoli, Italy

Hospital General Vall D'Hebron, Barcelona, Spain

Additional Information

Starting date: April 2013
Last updated: May 22, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017